Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04419519 | Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax | PHASE2 | ACTIVE NOT_RECRUITING | 81 | — | — | May 13, 2020 | May 1, 2027 | Jan 29, 2026 | 9 | United States |
This will be described as a percentage of all patients with available data at 12 cycles of follow up (evaluable population).
| Arm | Type | Description |
|---|---|---|
| Venetoclax monotherapy | EXPERIMENTAL | - |
| Venetoclax with anti-CD20 monoclonal antibody | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Venetoclax monotherapy | DRUG | Venetoclax monotherapy |
| Venetoclax with anti CD20 monoclonal antibody | DRUG | Venetoclax with anti CD20 monoclonal antibody |
Screening Phase Inclusion Criteria: * ≥ 18-years-old * Diagnosis of chronic lymphocytic leukemia or small lymphocytic lymphoma confirmed by the enrolling institution * Receiving treatment or planning to receive treatment within 30 days with a venetoclax-based regimen as defined below: * Venetocl...